A multicenter phase II study evaluating denosumab (XGEVA) in combination with nivolumab (OPDIVO) as second-line therapy for patients with stage IV non-small&NDASH;cell lung cancer (squamous and non-squamous) with bone metastases
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DENIVOS
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.
- 12 Sep 2018 Status changed from recruiting to not yet recruiting.
- 01 Aug 2018 New trial record